Daily PubMed evidence board
Association of the angiotensin II type 1 receptor A1166C polymorphism with essential hypertension in the Chinese population: a meta-analysis with ethnic and geographic subgroup analyses.
This meta-analysis combined 17 studies from China to ask whether a common variant in the angiotensin II type 1 receptor gene (called A1166C) is linked to…
Signal score58Research triage score
CertaintyModerateVerify in full text
PMID42159043Source identifier
Research triage, not medical advice
Do not use this summary, score, or benefit-cost estimate to diagnose, treat, prescribe, or change care without reviewing the full study and consulting qualified professionals.
Verify before acting
Check full-text methods, eligibility, outcomes, risk of bias, harms, conflicts, funding, replication, and applicability.
Plain-English signal
This meta-analysis combined 17 studies from China to ask whether a common variant in the angiotensin II type 1 receptor gene (called A1166C) is linked to essential hypertension. Across the pooled studies, people carrying the C allele (or the AC/CC genotypes) had a modestly higher odds of having high blood pressure compared with people with the A allele. The association appeared stronger in Han and Yi ethnic groups and in northern/northwestern regions, but the authors caution that subgroup results need confirmation. The authors call for larger, prospective studies with standardized blood pressure measurement to confirm whether this gene variant truly increases risk and whether it could help identify higher-risk people.
Why it matters
- Essential hypertension (EH) is a common, multifactorial disease with major public-health impact in China; identifying genetic risk variants can inform risk stratification and etiologic research.
- The AT1R A1166C polymorphism relates directly to the renin-angiotensin system, a therapeutic target in hypertension; a genetic association could influence mechanistic studies and priorities for population screening research.
- The study reports ethnic (Han, Yi) and regional (northern/northwestern China) differences in association strength, which could affect equity and targeting of future genetic risk assessments or prevention studies.
Primary outcomes
- Association of AC/CC genotype with essential hypertension (pooled OR = 1.34, 95% CI: 1.07-1.69) as reported in abstract
- Association of C allele with essential hypertension (pooled OR = 1.44, 95% CI: 1.14-1.82) as reported in abstract
Effect summary
Abstract-reported pooled estimates from 17 studies: carriers of the AC/CC genotype showed higher odds of EH (OR 1.34, 95% CI 1.07-1.69) and the C allele was associated with increased EH risk (OR 1.44, 95% CI 1.14-1.82). Stronger associations were reported in Han and Yi ethnic subgroups and in northern/northwestern regions; authors advise cautious interpretation and call for large prospective studies.
Benefit-cost lens
| Quick take | This meta-analysis reports a modest association between the AT1R A1166C C allele (and AC/CC genotypes) and essential hypertension in Chinese populations; benefit-cost claims for screening or intervention require absolute risks, prospective validation, and cost estimates. |
|---|---|
| BCR anchor | 2 |
| Time horizon | 3 |
| Discount rate | 0.03 |
| Assumptions | Abstract-only triage; effect sizes come from aggregated case-control studies included in the meta-analysis. Full-text needed to verify study inclusion, genotype assessment methods, adjustment for confounders, and applicability to prospective screening. |
Benefit-cost fields are assumptions-based unless explicitly source-derived. Treat them as prompts for deeper economic review.
Risk of bias
| Tool | rapid-abstract-screen |
|---|---|
| Verdict | Some concerns |
| Notes | Assessment based solely on the PubMed abstract and metadata. Meta-analysis of case-control studies can be vulnerable to population stratification, inconsistent phenotype definition, selective reporting, and study overlap; full-text inspection needed to evaluate study quality, heterogeneity sources, confounding control, and sensitivity analyses. |
Harms, equity, conflicts & implementation
| Implementation | Before any implementation: obtain full-text for methodological details, verify allele prevalence in target populations, estimate absolute risk differences, consult clinical genetics and hypertension experts, model costs and downstream pathways, and pilot in a prospective cohort with standardized blood pressure measurement. |
|---|---|
| Equity impact | Unclear from abstract. The reported ethnic and regional heterogeneity suggests potential differential predictive value or relevance across subgroups; equity implications depend on access to genetic testing and representativeness of source studies. |
| Harms | Harms are not reported in the abstract. Potential harms of acting on this signal (e.g., genetic screening) include false reassurance or anxiety, misclassification, unnecessary interventions, and resource diversion; full-text and implementation-specific assessment required. |
| Replication | Unknown from abstract-level triage; meta-analysis pooled multiple studies but prospective replication is recommended by authors. |
Source links — verify original
Use PubMed and full-text links to confirm methods, population, outcomes, harms, conflicts, and applicability.